AeroLeads people directory · profile
Anton Neschadim Email & Phone Number
CEO
at
Immunobiochem Corporation
1 work email found
@immunobiochem.com
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
CEO
Location
Toronto, Ontario, Canada
Company size
Who is Anton Neschadim? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Anton Neschadim is listed as CEO at Immunobiochem Corporation, a company with 3 employees, based in Toronto, Ontario, Canada. AeroLeads shows a work email signal at immunobiochem.com and a matched LinkedIn profile for Anton Neschadim.
Anton Neschadim previously worked as Venture Capital, Senior Advisor at Greensky Ventures and Director at Immunobiochem Corporation. Anton Neschadim holds Executive Education, Mergers & Acquisitions from Harvard Business School Executive Education.
Company email context
Email format at Immunobiochem Corporation
This section adds company-level context without repeating Anton Neschadim's masked contact details.
*@immunobiochem.com
71% confidence
AeroLeads found 1 current-domain work email signal for Anton Neschadim. Compare company email patterns before reaching out.
Profile bio
About Anton Neschadim
I am a biomedical industry executive, scientist, innovator, entrepreneur and venture capitalist with more than 20 years of combined industry and academic experience in research, drug development and venture capital. My experience and education bridges business administration and biomedical research, and enabled me to effectively lead and manage therapeutic drug development and R&D efforts in the biotechnology industry. My venture capital investment experience spans deal sourcing, evaluation and due diligence of seed to series A investment opportunities across biotech, health tech and deep tech sectors.With an infinite passion for the transformative benefits of biomedical research and biotechnology to our society, I am an integrative thinker employing my multi-disciplinary experience to advance the development of therapeutics that can address significant unmet clinical need.I am known for developing novel biological therapeutics and gene therapy treatment modalities, and published scientific works and patents across all major areas of biomedical research, including immunology, oncology, regenerative medicine, gene therapy and biological chemistry.Specialties: Biomedical Research, Drug Development, Biotechnology Consulting, Venture Capital, Board Management, Non-for-Profit Experience
Listed skills include Biotechnology, Molecular Biology, Immunology, Biochemistry, and 34 others.
Current workplace
Anton Neschadim's current company
Company context helps verify the profile and gives searchers a useful next step.
Immunobiochem Corporation
10 roles · 24 years
Anton Neschadim work experience
A career timeline built from the work history available for this profile.
Venture Capital, Senior Advisor
CurrentGreenSky Ventures, investing from its GreenSky Accelerator Funds, is a venture capital fund focused on making Seed and Series A round investments in high-growth, early-stage opportunities. Rebranded from GreenSky Capital Inc., the GreenSky Accelerator Funds have access to a robust network of deal flow and takes an institutional approach to early-stage.
2016 - Present
~10 yrs 5 mos
Ceo
CurrentImmunoBiochem is developing novel tumor microenvironment-targeted potentiated biologics for oncology, designed to overcome the challenges associated with tumor heterogeneity that limit the impact of targeted therapeutics. ImmunoBiochem's internalizing antibody-drug conjugates (ADCs) are based on fully-human antibodies developed using state-of-the-art phage.
2015 - Present
~11 yrs 5 mos
Director
CurrentImmunoBiochem is developing novel tumor microenvironment-targeted potentiated biologics for oncology, designed to overcome the challenges associated with tumor heterogeneity that limit the impact of targeted therapeutics. ImmunoBiochem's internalizing antibody-drug conjugates (ADCs) are based on fully-human antibodies developed using state-of-the-art phage.
2007 - Present
~19 yrs 5 mos
Chief Executive
CurrentNanovista, based at JLABS@Toronto, is developing novel mutli-modality imaging agent for surgical oncology to enable intraoperative visualization of solid tumors and tumor margins.
2020 - Present
~6 yrs 5 mos
Director, Drug Development
Armour Therapeutics Inc.
Armour Therapeutics is a biopharmaceutical company focused on the development of a new class of anti-hormone therapeutics for the treatment of reproductive tissue-based cancers. Armour’s compounds are designed to maintain an anti-androgen effect in patients developing resistance to currently marketed anti-hormonals, with the additional benefit of blocking.
2010 - 2015
~5 yrs
Organizing Committee, Revenue Development Sub-Committee Co-Chair
Canadian Science Policy Conference
The Canadian Science Policy Conference (CSPC) was founded in 2009 by a diverse group of young and passionate professionals from industry, academia, and science-based governmental departments. CSPC serves as an inclusive, non-partisan and national forum uniting stakeholders, strengthening dialogue, and enabling action with respect to current and emerging.
Sep 2008 - 2013
Founding Member Of The Board Of Directors
The Canadian Science Policy Conference (CSPC) was founded in 2009 by a diverse group of young and passionate professionals from industry, academia, and science-based governmental departments. CSPC serves as an inclusive, non-partisan and national forum uniting stakeholders, strengthening dialogue, and enabling action with respect to current and emerging.
Nov 2009 - Jan 2012
Research
2005 - 2011
~6 yrs
2002 - 2004
~2 yrs
9 education records
Anton Neschadim education
Executive Education, Mergers & Acquisitions
Harvard Business School Executive Education
Executive Education, Negotiation For Executives, Interpersonal Communication Strategies For Executives
Mit Sloan Executive Education
Executive Program In Leadership
Stanford University Graduate School Of Business
Executive Education, Negotiation Strategies
Yale School Of Management
Executive Education, Value Measurement For Health Care
Harvard Business School Executive Education
Master Of Business Administration (M.B.A.), Evening Part-Time
University Of Toronto - Rotman School Of Management
Phd, Department Of Medical Biophysics - Gene Therapy
University Of Toronto
Msc, Department Of Immunology
University Of Toronto
Hon. B.Sc., Immunology Specialist, Biological Chemistry Specialist
University Of Toronto - University College
FAQ
Frequently asked questions about Anton Neschadim
Quick answers generated from the profile data available on this page.
What company does Anton Neschadim work for?
Anton Neschadim works for Immunobiochem Corporation.
What is Anton Neschadim's role at Immunobiochem Corporation?
Anton Neschadim is listed as CEO at Immunobiochem Corporation.
What is Anton Neschadim's email address?
AeroLeads has found 1 work email signal at @immunobiochem.com for Anton Neschadim at Immunobiochem Corporation.
Where is Anton Neschadim based?
Anton Neschadim is based in Toronto, Ontario, Canada while working with Immunobiochem Corporation.
What companies has Anton Neschadim worked for?
Anton Neschadim has worked for Immunobiochem Corporation, Greensky Ventures, Nanovista Inc., Armour Therapeutics Inc., and Canadian Science Policy Conference.
How can I contact Anton Neschadim?
You can use AeroLeads to view verified contact signals for Anton Neschadim at Immunobiochem Corporation, including work email, phone, and LinkedIn data when available.
What schools did Anton Neschadim attend?
Anton Neschadim holds Executive Education, Mergers & Acquisitions from Harvard Business School Executive Education.
What skills is Anton Neschadim known for?
Anton Neschadim is listed with skills including Biotechnology, Molecular Biology, Immunology, Biochemistry, Drug Development, Research, Life Sciences, and Cell.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial